Opinion|Videos|September 11, 2024

Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.

Episodes in this series

Video content above is prompted by the following:

  • What are common misconceptions regarding the timing of therapy initiation and discontinuation?
  • What has research shown regarding outcomes for initiating therapy before age 7 years or discontinuing therapy after age 12 years?
  • What consideration should clinicians give about the time to first menses after treatment cessation?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Latest CME

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
Video

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Paul G. Auwaerter, MD, MBA; Paul P. Doghramji, MD, FAAFP; Aruna Subramanian, MD

View more
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
Video

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

View more
Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies
Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

View more
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

View more
Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis
Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

View more
Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

View more
Burst CME: Targeted Therapy for Optimal Psoriasis Management
Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

View more
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

View more
Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update
Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

View more
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us